Le Lézard
Classified in: Health, Business
Subject: STS

InMode Ltd. Announces 2-for-1 Share Split


YOKNEAM, Israel, Sept. 17, 2021 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode" or the "Company"), a leading global provider of innovative medical technologies, today announced a two-for-one (2:1) share split of the Company's ordinary shares, with a record date of September 27, 2021 (the "Record Date"). The share split will take effect on September 30, 2021, and the Company's ordinary shares will begin trading on a post-split basis on the Nasdaq Global Select Market on October 1, 2021.

InMode Logo

On September 30, 2021, every share of the Company's pre-split ordinary shares held by a shareholder as of the Record Date, including shares subject to outstanding stock options and shares available for grant under the Company's equity incentive plans, will automatically be split into two shares of the Company's post-split ordinary shares. The share split will affect all shareholders uniformly and will not affect any shareholder's ownership percentage. The Company's shareholders will not be required to surrender their existing certificates to receive the shares to be issued pursuant to the share split, which will be effected by delivering additional shares in uncertificated book-entry form by American Stock Transfer & Trust Company, the Company's transfer agent.

The share split was approved by the Company's board of directors on September 14, 2021.

About InMode

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio-frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically-accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.

Logo - https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg

Company Contact:

Yair Malca

Chief Financial Officer

Phone: (949) 305-0108

Email: [email protected]

Investor Relations Contact:

Miri Segal

MS-IR LLC

Phone: (917) 607-8654

Email: [email protected]

SOURCE InMode Ltd.


These press releases may also interest you

at 18:05
Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

at 14:06
Red Door Community Raises more than $300,000 at Their Annual Luncheon Celebrating Women Working and Living with Cancer
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

at 14:05
Easy Eats Pandemanila brand Kalihim (Philippine Bread Rolls) recalled due to undeclared egg
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 13:27
Industrial Automation Market In Life Sciences Industry size is set to grow by USD 5.06 bn from 2024-2028, growing global demand for healthcare services to boost the market growth, Technavio
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 11:03
MODULAR ATP Study of the mCRMtm System Meets Primary Safety and Efficacy Endpoints
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

More news about Health...


News published on and distributed by: